Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease

被引:3
|
作者
De, Tanima [1 ]
Zhang, Honghong [1 ]
Alarcon, Cristina [1 ]
Lec, Bianca [1 ]
Avitia, Juan [1 ]
Smithberger, Erin [2 ]
Chen, Chuyu [1 ]
Horvath, Minnie [1 ]
Kwan, Sara [3 ]
Young, Mary [3 ]
Adhikari, Sarbani [3 ]
Kwon, John [2 ]
Pacheco, Jennifer [1 ]
Jarvik, Gail [4 ,5 ]
Wei, Wei-Qi [6 ]
Mentch, Frank [7 ]
Hakonarson, Hakon [7 ,8 ]
Sleiman, Patrick [7 ,8 ]
Gordon, Adam [1 ]
Harley, John [9 ,10 ]
Linneman, Jim [11 ]
Hebbring, Scott [12 ]
Parisiadou, Loukia [1 ]
Perera, Minoli A. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Pharmacol, Chicago, IL 60611 USA
[2] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA
[3] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA
[4] Univ Washington, Dept Med Med Genet, Med Ctr, Seattle, WA 98195 USA
[5] Univ Washington, Med Ctr, Dept Genome Sci, Seattle, WA 98195 USA
[6] Vanderbilt Univ, Med Ctr, Biomed Informat, Nashville, TN USA
[7] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA
[8] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA
[9] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol CAGE, Cincinnati, OH 45229 USA
[10] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA
[11] Marshfield Clin Res Inst, Off Res Comp & Analyt, Marshfield, WI USA
[12] Marshfield Clin Res Inst, Ctr Precis Med Res, Marshfield, WI USA
关键词
anti-TNF alpha; genome-wide association study; inflammatory bowel disease; primary nonresponse; single-nucleotide polymorphism; GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; INFLIXIMAB; MANIFESTATIONS; POLYMORPHISMS; VARIANTS; DRUG; METAANALYSIS; IMPUTATION;
D O I
10.1097/FPC.0000000000000445
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives Primary nonresponse (PNR) to antitumor necrosis factor-alpha (TNF alpha) biologics is a serious concern in patients with inflammatory bowel disease (IBD). We aimed to identify the genetic variants associated with PNR. Patients and methods Patients were recruited from outpatient GI clinics and PNR was determined using both clinical and endoscopic findings. A case-control genome-wide association study was performed in 589 IBD patients and associations were replicated in an independent cohort of 293 patients. Effect of the associated variant on gene expression and TNF alpha secretion was assessed by cell-based assays. Pleiotropic effects were investigated by Phenome-wide association study (PheWAS). Results We identified rs34767465 as associated with PNR to anti-TNF alpha therapy (odds ratio: 2.07, 95% CI, 1.46-2.94, P = 2.43 x 10(-7), [replication odds ratio: 1.8, 95% CI, 1.04-3.16, P = 0.03]). rs34767465 is a multiple-tissue expression quantitative trait loci for FAM114A2. Using RNA-sequencing and protein quantification from HapMap lymphoblastoid cell lines (LCLs), we found a significant decrease in FAM114A2 mRNA and protein expression in both heterozygous and homozygous genotypes when compared to wild type LCLs. TNF alpha secretion was significantly higher in THP-1 cells [differentiated into macrophages] with FAM114A2 knockdown versus controls. Immunoblotting experiments showed that depletion of FAM114A2 impaired autophagy-related pathway genes suggesting autophagy-mediated TNF alpha secretion as a potential mechanism. PheWAS showed rs34767465 was associated with comorbid conditions found in IBD patients (derangement of joints [P = 3.7 x 10(-4)], pigmentary iris degeneration [P = 5.9 x 10(-4)], diverticulum of esophagus [P = 7 x 10(-4)]). Conclusions We identified a variant rs34767465 associated with PNR to anti-TNF alpha biologics, which increases TNF alpha secretion through mechanism related to autophagy. rs34767465 may also explain the comorbidities associated with IBD.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [21] Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy
    Iriarte, Ainara
    Zaera, Celia
    Bachiller-Corral, Javier
    Lopez-Sanroman, Antonio
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (02): : 117 - 121
  • [22] Anti-TNF Antibody Therapy for Inflammatory Bowel Disease During Pregnancy: A Clinical Review
    El Mourabet, Marwa
    El-Hachem, Sandra
    Harrison, Janet R.
    Binion, David G.
    CURRENT DRUG TARGETS, 2010, 11 (02) : 234 - 241
  • [23] Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
    Zeng, Zhen
    Lin, Hao
    Jiang, Mingshan
    Yuan, Jing
    Li, Xi
    Jia, Yongbin
    Yang, Li
    Zhang, Hu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [24] The effect of anti-TNF therapy on thyroid function in patients with inflammatory bowel disease
    Paschou, Stavroula A.
    Palioura, Eleni
    Kothonas, Fotios
    Myroforidis, Alexandros
    Loi, Vasiliki
    Poulou, Androniki
    Goumas, Konstantinos
    Effraimidis, Grigoris
    Vryonidou, Andromachi
    ENDOCRINE JOURNAL, 2018, 65 (11) : 1121 - 1125
  • [25] Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease
    Wang, Ming-Hsi
    Friton, Jessica J.
    Raffals, Laura E.
    Leighton, Jonathan A.
    Pasha, Shabana F.
    Picco, Michael F.
    Cushing, Kelly C.
    Monroe, Kelly
    Nix, Billy D.
    Newberry, Rodney D.
    Faubion, William A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (08) : 1036 - 1043
  • [26] Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease
    Lobaton, T.
    Ferrante, M.
    Rutgeerts, P.
    Ballet, V.
    Van Assche, G.
    Vermeire, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (04) : 441 - 451
  • [27] Current and future anti-TNF therapy for inflammatory bowel disease
    Osterman M.T.
    Lichtenstein G.R.
    Current Treatment Options in Gastroenterology, 2007, 10 (3) : 195 - 207
  • [28] Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series
    Altwegg, Romain
    Combes, Roman
    Laharie, David
    De Ledinghen, Victor
    Radenne, Sylvie
    Conti, Filomena
    Chazouilleres, Olivier
    Duvoux, Christophe
    Dumortier, Jerome
    Leroy, Vincent
    Treton, Xavier
    Durand, Francois
    Dharancy, Sebastien
    Nachury, Maria
    Goutorbe, Felix
    Lamblin, Geraldine
    Boivineau, Lucile
    Peyrin-Biroulet, Laurent
    Pageaux, Georges-Philippe
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (07) : 668 - 674
  • [29] Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
    Levin, Alon D.
    Wildenberg, Manon E.
    van den Brink, Gijs R.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (08) : 989 - 997
  • [30] Tuberculous Chemoprophylaxis Requirements and Safety in Inflammatory Bowel Disease Patients Prior to Anti-TNF Therapy
    Zabana, Yamile
    Domenech, Eugeni
    San Roman, Antonio Lopez
    Beltran, Belen
    Luis Cabriada, Jose
    Saro, Cristina
    Aramendiz, Robert
    Ginard, Daniel
    Hinojosa, Joaquin
    Gisbert, Javier P.
    Manosa, Miriam
    Cabre, Eduard
    Gassull, Miquel A.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (10) : 1387 - 1391